Bellecapital International Ltd. Sells 553 Shares of PRA Health Sciences Inc (NASDAQ:PRAH)

Share on StockTwits

Bellecapital International Ltd. decreased its position in shares of PRA Health Sciences Inc (NASDAQ:PRAH) by 1.1% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 47,553 shares of the medical research company’s stock after selling 553 shares during the period. PRA Health Sciences makes up approximately 2.9% of Bellecapital International Ltd.’s holdings, making the stock its 11th largest holding. Bellecapital International Ltd. owned approximately 0.07% of PRA Health Sciences worth $4,715,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in PRAH. Carroll Financial Associates Inc. increased its holdings in shares of PRA Health Sciences by 7.6% in the first quarter. Carroll Financial Associates Inc. now owns 1,517 shares of the medical research company’s stock worth $167,000 after buying an additional 107 shares during the period. Commonwealth of Pennsylvania Public School Empls Retrmt SYS increased its holdings in shares of PRA Health Sciences by 1.3% in the first quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 10,390 shares of the medical research company’s stock worth $1,146,000 after buying an additional 129 shares during the period. Crossmark Global Holdings Inc. increased its holdings in shares of PRA Health Sciences by 1.6% in the first quarter. Crossmark Global Holdings Inc. now owns 8,840 shares of the medical research company’s stock worth $975,000 after buying an additional 140 shares during the period. Kendall Capital Management increased its holdings in shares of PRA Health Sciences by 1.5% in the first quarter. Kendall Capital Management now owns 9,907 shares of the medical research company’s stock worth $1,093,000 after buying an additional 142 shares during the period. Finally, CENTRAL TRUST Co increased its holdings in shares of PRA Health Sciences by 28.2% in the first quarter. CENTRAL TRUST Co now owns 842 shares of the medical research company’s stock worth $93,000 after buying an additional 185 shares during the period. Institutional investors and hedge funds own 97.98% of the company’s stock.

PRA Health Sciences stock opened at $94.58 on Friday. The company has a debt-to-equity ratio of 1.11, a quick ratio of 0.99 and a current ratio of 0.99. The stock’s 50 day simple moving average is $98.27 and its two-hundred day simple moving average is $99.92. PRA Health Sciences Inc has a fifty-two week low of $82.12 and a fifty-two week high of $121.98. The stock has a market cap of $6.11 billion, a price-to-earnings ratio of 24.07, a PEG ratio of 1.29 and a beta of 1.12.

PRA Health Sciences (NASDAQ:PRAH) last issued its quarterly earnings results on Wednesday, July 31st. The medical research company reported $1.22 EPS for the quarter, topping analysts’ consensus estimates of $1.11 by $0.11. PRA Health Sciences had a return on equity of 26.64% and a net margin of 5.39%. The firm had revenue of $763.31 million for the quarter, compared to analysts’ expectations of $764.95 million. During the same period in the previous year, the firm posted $1.00 EPS. The business’s revenue for the quarter was up 5.6% compared to the same quarter last year. On average, analysts predict that PRA Health Sciences Inc will post 4.63 earnings per share for the current year.

Several analysts recently issued reports on PRAH shares. BidaskClub raised PRA Health Sciences from a “hold” rating to a “buy” rating in a research note on Wednesday, July 24th. Mizuho set a $100.00 target price on PRA Health Sciences and gave the stock a “hold” rating in a research note on Friday, May 3rd. Svb Leerink reissued a “market perform” rating on shares of PRA Health Sciences in a research note on Tuesday, July 2nd. Finally, Leerink Swann started coverage on PRA Health Sciences in a research note on Tuesday, July 2nd. They issued a “market perform” rating and a $105.00 target price on the stock. Eight analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. The company currently has an average rating of “Hold” and an average price target of $113.40.

About PRA Health Sciences

PRA Health Sciences, Inc, a contract research organization, provides outsourced clinical development and data solution services to the biotechnology and pharmaceutical industries worldwide. The company operates in two segments, Clinical Research and Data Solutions. The Clinical Research segment offers product registration services, including clinical trial management, project management, regulatory affairs, therapeutic expertise, clinical operations, data and programming, safety and risk management, biostatistics and medical writing, quality assurance, and late phase services.

Featured Article: What is a Roth IRA?

Institutional Ownership by Quarter for PRA Health Sciences (NASDAQ:PRAH)

Receive News & Ratings for PRA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.